Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities
Nimotuzumab is a humanized monoclonal antibody that binds specifically to human epidermal growth factor receptor, blocking receptor activation. Evidence of its radiosensitizing capacity has been widely evaluated. This article integrates published research findings regarding the role of nimotuzumab i...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729249/ |